$0.3993−$0.0611 (−13.27%) on the dayAs of the close; data may be delayed.
MIST price, last 12 months
$2.95$0.3650
Daily closes over the last 260 trading sessions: −76.6%. Highest close $2.95 on , lowest $0.3650 on . Market data may be delayed.
Key stats
Previous close
$0.4604
Open
$0.4655
Day range
$0.3901 – $0.4655
52-week range
$0.3620 – $3.06
Volume
1.3M
Avg volume (20 days)
2.2M
Market cap
$64.7M
Performance
1W−25.0%
1M−44.5%
3M−62.5%
6M−72.3%
YTD−80.7%
1Y−83.3%
vs S&P 500, 1Y−88.5 pts
Technicals and fundamentals
About Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Chart MIST with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full MIST chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)19.6%average true range, % of price
52w low $0.362052w high $3.06
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)−0.6
PEG—
Price / sales—
Price / book−7.42
EV / EBITDA—
Company figures as of Nov 20, 2026.
Analysts
ConsensusStrong buy1.4 on 1 (strong buy) to 5 (strong sell)
Analysts7
Average target$3.86+889.0% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Mar 19, 2027 (in 118 days)A year after its Mar 20, 2026 results release; the last came Nov 13, 2026. An estimate from its SEC filings, not a date the company announced.
Seasonality
-5.6
J
-13.0
F
-4.1
M
+20.8
A
-2.9
M
-3.2
J
+0.2
J
+5.8
A
+2.4
S
-14.8
O
+20.6
N
-11.2
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−5
−10
−30
+51
−21
−6
−17
+5
−25
−16
−64%
2025
−17
−17
−51
+65
+23
+20
−25
+27
+9
−4
+40
−25
−14%
2024
−4
+5
+7
−8
−9
−12
+9
−1
+7
−5
+37
+19
+41%
2023
−8
−14
+25
−8
+9
−28
+13
−17
+16
−17
+30
−50
−58%
2022
+6
−29
+30
+4
−16
+10
+21
+16
+6
−45
−2
−19
−40%
2021
−1
−3
+20
+15%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The announcement is a routine corporate action regarding employee compensation. While it indicates the company is hiring and growing, the grant of options at $0.72 per share is a standard HR practice with no material business impact disclosed. The article contains no information about financial performance, clinical results, or strategic developments that would warrant positive or negative sentiment.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.